Keyword: Merck KGaA

Principia Biopharma has filed to raise up to $86.3 million in its IPO to carry its lead BTK inhibitor into phase 3.

MilliporeSigma and InnoCore will work to offer a delivery platform for sustained-release formulations for “virtually any” injectable biologic.

Vaccinex filed a $46 million Nasdaq IPO to support its development of antibodies and conjugates targeting neurodegenerative diseases and cancer.

The Temasek-led series C round comes five months after Akili posted positive data from a pivotal clinical trial of its digital medicine.

Evobrutinib cut gadolinium-enhancing T1 lesions by more than placebo, but Merck has yet to quantify the difference or say if it beat Tecfidera.

The round sets up the JLABS resident to use advances in synthetic biology to create more targeted, controllable cell and gene therapies.

Syndax is set to put its cocktail through a phase 1b solid tumor trial ahead of midphase trials to demonstrate its safety and efficacy. 

NICE leader joined ABPI; Heptares co-founder will lead Merck’s new London center; Sanofi named a business transformation head.

The pact sets Merck up to work with researchers at CRUK’s unit at the ICR on three preclinical oncology projects.

Roche joins Merck KGaA as pharma parter for Forty Seven's CD47-targeting antibody, which blocks a "don't eat me" signal sent out by malignant cells.